See more : Hexaom S.A. (ALHEX.PA) Income Statement Analysis – Financial Results
Complete financial analysis of IntelGenx Technologies Corp. (IGXT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of IntelGenx Technologies Corp., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Bliss GVS Pharma Limited (BLISSGVS.NS) Income Statement Analysis – Financial Results
- PT Mulia Boga Raya Tbk (KEJU.JK) Income Statement Analysis – Financial Results
- Pennsylvania Warehousing Safe Deposit (PAWH) Income Statement Analysis – Financial Results
- PureTech Health plc (PRTC.L) Income Statement Analysis – Financial Results
- Syschem (India) Limited (SYSCHEM.BO) Income Statement Analysis – Financial Results
IntelGenx Technologies Corp. (IGXT)
About IntelGenx Technologies Corp.
IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0040/2014, INT0052/2020, INT0053/2020, and INT0054/2020. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.04M | 950.00K | 1.54M | 1.54M | 742.00K | 1.82M | 5.20M | 5.22M | 5.10M | 1.66M | 948.00K | 1.21M | 440.00K | 1.34M | 1.28M | 976.61K | 835.42K | 265.90K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.73M | 1.86M | 2.26M | 1.48M | 0.00 | 0.00 | 373.00K | 319.00K | 433.00K | 61.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -694.00K | -908.00K | -721.00K | 67.00K | 742.00K | 1.82M | 4.82M | 4.90M | 4.66M | 1.60M | 948.00K | 1.21M | 440.00K | 1.34M | 1.28M | 976.61K | 835.42K | 265.90K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | -66.79% | -95.58% | -46.97% | 4.34% | 100.00% | 100.00% | 92.82% | 93.89% | 91.50% | 96.32% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 3.43M | 3.03M | 2.72M | 2.64M | 3.77M | 5.10M | 2.62M | 1.77M | 1.03M | 1.08M | 561.00K | 1.72M | 1.34M | 1.57M | 1.42M | 2.09M | 603.40K | 510.41K | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.65M | 1.51M | 2.73M | 1.38M | 1.46M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.76M | 4.70M | 3.75M | 4.44M | 5.80M | 5.00M | 3.97M | 3.61M | 2.07M | 2.29M | 1.95M | 1.65M | 1.51M | 2.73M | 1.38M | 1.46M | 919.62K | 488.60K | 9.91K | 7.55K | 108.00 |
| Other Expenses | 0.00 | 777.00K | 791.00K | 734.00K | 718.00K | 719.00K | 735.00K | 511.00K | 171.00K | 74.00K | 72.00K | 46.00K | 37.00K | 44.00K | -237.90K | -376.84K | -132.37K | 33.91K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 8.18M | 8.51M | 7.26M | 7.81M | 10.29M | 10.82M | 7.32M | 5.88M | 3.28M | 3.44M | 2.59M | 3.41M | 2.89M | 4.34M | 2.57M | 3.17M | 1.57M | 1.03M | 9.91K | 7.55K | 108.00 |
| Cost & Expenses | 10.68M | 10.36M | 9.52M | 7.81M | 10.29M | 10.82M | 7.69M | 6.20M | 3.71M | 3.44M | 2.59M | 3.41M | 2.89M | 4.34M | 2.57M | 3.17M | 1.57M | 1.03M | 9.91K | 7.55K | 108.00 |
| Interest Income | 41.00K | 4.00K | 152.00K | 422.00K | 97.00K | 11.00K | 11.00K | 4.00K | 28.00K | 34.00K | 0.00 | 10.00K | 0.00 | 0.00 | 0.00 | 30.86K | 27.36K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.63M | 1.28M | 1.49M | 1.20M | 1.21M | 1.12M | 569.00K | 203.00K | 123.00K | 0.00 | 0.00 | 3.00K | 3.00K | 98.00K | 784.40K | 766.14K | 349.11K | 54.72K | 1.22K | 297.00 | 0.00 |
| Depreciation & Amortization | 766.00K | 777.00K | 791.00K | 734.00K | 718.00K | 719.00K | 735.00K | 511.00K | 171.00K | 74.00K | 72.00K | 46.00K | 37.00K | 44.00K | 44.60K | 51.77K | 42.01K | 33.91K | 0.00 | 0.00 | 0.00 |
| EBITDA | -7.69M | -8.64M | -7.04M | -5.11M | -8.74M | -8.28M | -1.76M | -470.00K | 1.59M | -1.71M | -1.57M | -2.22M | -2.60M | -3.14M | -1.24M | -2.45M | -948.17K | -731.53K | -146.53K | -7.55K | -108.00 |
| EBITDA Ratio | -739.65% | -908.63% | -458.57% | -330.83% | -1,177.22% | -453.29% | -33.63% | -8.93% | 31.11% | -102.83% | -165.30% | -178.81% | -547.50% | -221.24% | -97.11% | -219.13% | -68.71% | -290.98% | 0.00% | 0.00% | 0.00% |
| Operating Income | -9.49M | -9.41M | -7.98M | -6.26M | -9.55M | -9.00M | -2.49M | -981.00K | 1.39M | -1.78M | -1.64M | -2.21M | -2.45M | -3.00M | -1.29M | -2.19M | -729.62K | -767.02K | -9.91K | -7.55K | -108.00 |
| Operating Income Ratio | -913.47% | -990.84% | -520.00% | -405.70% | -1,287.06% | -493.31% | -47.99% | -18.79% | 27.20% | -107.29% | -172.89% | -182.62% | -555.91% | -224.53% | -100.60% | -224.43% | -87.34% | -288.46% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -436.00K | -1.28M | -1.34M | -780.00K | -1.11M | -1.11M | -558.00K | -199.00K | -95.00K | 34.00K | 0.00 | 10.00K | 172.00K | -558.00K | -686.70K | -306.67K | -196.81K | -14.12K | 35.29K | 0.00 | 0.00 |
| Income Before Tax | -9.93M | -10.69M | -9.32M | -7.04M | -10.66M | -10.11M | -3.05M | -1.18M | 1.29M | -1.75M | -1.64M | -2.25M | -2.45M | -3.10M | -2.07M | -2.96M | -1.16M | -781.14K | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -955.44% | -1,125.26% | -607.04% | -456.22% | -1,436.66% | -554.17% | -58.73% | -22.61% | 25.34% | -105.24% | -172.89% | -186.26% | -557.27% | -231.56% | -161.94% | -302.88% | -139.44% | -293.77% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 1.28M | -6.00K | 1.20M | 1.21M | 11.00K | 11.00K | 4.00K | 28.00K | 0.00 | 0.00 | 3.00K | 3.00K | 98.00K | -130.30K | -151.58K | -64.08K | 14.12K | 11.12K | 7.84K | 108.00 |
| Net Income | -9.93M | -11.97M | -9.31M | -8.25M | -11.87M | -10.11M | -3.05M | -1.18M | 1.29M | -1.75M | -1.64M | -2.25M | -2.45M | -3.10M | -1.94M | -2.81M | -1.10M | -781.14K | -11.12K | -7.84K | -108.00 |
| Net Income Ratio | -955.44% | -1,259.68% | -606.64% | -534.07% | -1,599.33% | -554.17% | -58.73% | -22.61% | 25.34% | -105.24% | -172.89% | -186.26% | -557.27% | -231.56% | -151.75% | -287.36% | -131.77% | -293.77% | 0.00% | 0.00% | 0.00% |
| EPS | -0.06 | -0.07 | -0.07 | -0.08 | -0.13 | -0.14 | -0.05 | -0.02 | 0.01 | -0.03 | -0.03 | -0.05 | -0.06 | -0.09 | -0.08 | -0.14 | -0.07 | -0.05 | 0.00 | -0.01 | 0.00 |
| EPS Diluted | -0.06 | -0.07 | -0.07 | -0.08 | -0.13 | -0.14 | -0.05 | -0.02 | 0.01 | -0.03 | -0.03 | -0.05 | -0.06 | -0.09 | -0.08 | -0.14 | -0.07 | -0.05 | 0.00 | -0.01 | 0.00 |
| Weighted Avg Shares Out | 174.65M | 164.75M | 137.00M | 108.44M | 93.53M | 74.12M | 66.15M | 63.96M | 63.52M | 63.18M | 54.02M | 49.64M | 43.74M | 35.33M | 24.53M | 19.66M | 16.04M | 14.34M | 10.99M | 1.50M | 1.50M |
| Weighted Avg Shares Out (Dil) | 174.65M | 164.75M | 137.00M | 108.44M | 93.53M | 74.12M | 66.15M | 63.96M | 70.86M | 63.18M | 54.02M | 49.64M | 43.74M | 35.33M | 24.53M | 19.66M | 16.04M | 14.34M | 10.99M | 1.50M | 1.50M |
IntelGenx Technologies Corp. (IGXT) Q4 2023 Earnings Call Transcript
IntelGenx Technologies Corp. (IGXT) Q4 2023 Earnings Call Transcript
IntelGenx Reports Fourth Quarter and Full-Year 2023 Financial Results
SAINT LAURENT, Quebec, March 21, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today reported financial results for the three- and twelve-month periods ended December 31, 2023. All dollar amounts are expressed in U.S. currency, unless otherwise indicated,...
IntelGenx to Report Fourth Quarter and Full Year 2023 Financial Results on March 21, 2024 – Conference Call to Follow
SAINT LAURENT, Quebec, March 14, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its fourth quarter and full year 2023 financial results before market open on Thursday,...
IntelGenx Enters Into a Third Amended and Restated Loan Agreement With atai Life Sciences
SAINT LAURENT, Quebec, March 11, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (the “Company”) announces that its wholly-owned subsidiary, IntelGenx Corp. (“IntelGenx Corp.”), has entered into a third amended and restated loan agreement dated as of March 8,...
UPDATE -- IntelGenx Launches Preferred Share Regulation A Offering
SAINT LAURENT, Quebec, Feb. 20, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced the launch of a Regulation A offering of up to 2,000,000 shares of Series A Convertible Cumulative Preferred Stock (“Series A...
IntelGenx Launches Preferred Share Regulation A Offering
SAINT LAURENT, Quebec, Feb. 20, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced the launch of a Regulation A offering of up to 2,000,000 shares of Series A Convertible Cumulative Preferred Stock (“Series A...
IntelGenx Announces New Animal Health Partnership; Enters into Development and License Agreements for VetaFilm®
SAINT LAURENT, Quebec, Dec. 18, 2023 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that it has entered into development and license agreements (collectively the “Agreements”) with a wholly-owned subsidiary of Covenant Animal Health Partners, LLC...
IntelGenx Announces Closing of Previously Announced Subsequent Non-Brokered Private Placement With atai Life Sciences for Aggregate Gross Proceeds of US$750,000
SAINT LAURENT, Quebec, Dec. 05, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx” or the “Company”) announces the closing of the previously announced subsequent non-brokered private placement (the “Subsequent atai Subscription”) of 750 units (“US Units”) with atai...
IntelGenx Announces Shareholder Approval of Financing Transactions
SAINT LAURENT, Quebec, Nov. 28, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx” or the “Company”) is pleased to announce that, at its meeting held earlier today (the “Special Meeting”), the shareholders (the “Shareholders”) voted to approve all proposals related...
IntelGenx Receives Approval to Conduct 'MONTPARK' Montelukast VersaFilm® Phase 2 Clinical Trial in Patients with Parkinson's Disease
Phase 2 MONTPARK trial expected to begin recruiting patients in Q1 2024 Phase 2 MONTPARK trial expected to begin recruiting patients in Q1 2024
Source: https://incomestatements.info
Category: Stock Reports